486 related articles for article (PubMed ID: 33006786)
1. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
Hayakawa T; Yaguchi T; Kawakami Y
Cancer Sci; 2020 Dec; 111(12):4326-4335. PubMed ID: 33006786
[TBL] [Abstract][Full Text] [Related]
2. Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling.
Bazhin AV; von Ahn K; Fritz J; Werner J; Karakhanova S
Front Immunol; 2018; 9():2129. PubMed ID: 30356906
[TBL] [Abstract][Full Text] [Related]
3. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS; Arlauckas SP; Kohler RH; Trefny MP; Garren S; Piot C; Engblom C; Pfirschke C; Siwicki M; Gungabeesoon J; Freeman GJ; Warren SE; Ong S; Browning E; Twitty CG; Pierce RH; Le MH; Algazi AP; Daud AI; Pai SI; Zippelius A; Weissleder R; Pittet MJ
Immunity; 2018 Dec; 49(6):1148-1161.e7. PubMed ID: 30552023
[TBL] [Abstract][Full Text] [Related]
4. A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo.
Ishii K; Shimizu M; Kogo H; Negishi Y; Tamura H; Morita R; Takahashi H
Immunobiology; 2020 Jan; 225(1):151860. PubMed ID: 31812347
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
6. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
[TBL] [Abstract][Full Text] [Related]
7. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
8. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
[TBL] [Abstract][Full Text] [Related]
10. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
11. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; Guruceaga E; Lasarte JJ; Sarobe P
Oncotarget; 2017 Jan; 8(2):2659-2671. PubMed ID: 27926522
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
13. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H
Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
Kitamura H; Ohno Y; Toyoshima Y; Ohtake J; Homma S; Kawamura H; Takahashi N; Taketomi A
Cancer Sci; 2017 Oct; 108(10):1947-1952. PubMed ID: 28749573
[TBL] [Abstract][Full Text] [Related]
15. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
[TBL] [Abstract][Full Text] [Related]
16. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S
J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387
[TBL] [Abstract][Full Text] [Related]
18. Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma.
Alshamsan A
Immunopharmacol Immunotoxicol; 2012 Jun; 34(3):465-9. PubMed ID: 21999714
[TBL] [Abstract][Full Text] [Related]
19. Andrographolide potentiates PD-1 blockade immunotherapy by inhibiting COX2-mediated PGE2 release.
Liu W; Fan T; Li M; Zhang G; Guo W; Yang X; Jiang C; Li X; Xu X; Tang A; Liu K; Liu L; Kong L; Xu Q; Sun Y
Int Immunopharmacol; 2020 Apr; 81():106206. PubMed ID: 32018066
[TBL] [Abstract][Full Text] [Related]
20. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
